Apollo Cancer Centre in collaboration with Datar Cancer Genetics launches Revolutionary Blood Test for early detection of Breast Cancer, Health News, ET HealthWorld

Apollo Cancer Center, in partnership with Datar Cancer Genetics, launches revolutionary blood test for early detection of breast cancerHyderabad, June 2022: Awarded the best private cancer hospital in India, Apollo Cancer Centers is committed to continued investment in the most advanced technologies in cancer care. stages in asymptomatic individuals with high accuracy, allowing timely diagnosis and treatment to save lives.

An increase in the number of breast cancers and the social construction associated with discussions about breast cancer has led to one of the most important developments in the history of technological advances in oncology. Guided by the same drive to bring cancer conversations to the fore, Apollo Cancer Centers through this launch is calling on women to get screened in the easiest way through a blood test to learn about their susceptibility to breast cancer. With a simple sample of a small amount of blood, EasyCheck-Breast can now help detect breast cancer even before the first stage. The EasyCheck will be available in all Apollo Cancer Centers across India on June 22.

Commenting on the occasion, Dr. Prathap Reddy, Founder and President of Apollo Hospitals, said: “In line with our mission to spread awareness about early cancer detection and provide world-class cancer treatment, the launch of EasyCheck Breast marks a significant success toward high-tech advancements that ensures timely diagnosis and treatment to lower the death rate. This partnership with Datar Cancer Genetics has delivered a breakthrough achievement, and at Apollo Cancer Centers, we are well equipped to diagnose breast cancer with best-in-class advances and treatments.”

Speaking about the product, Rajan Datar, Founder and Chairman of Datar Cancer Genetics, said: “Unfortunately, most cancers are discovered at an advanced stage, requiring more intensive and expensive treatments, which carry a greater risk of debilitating side effects and treatment failures. The result of years of collaborative international research and innovation, EasyCheck-Borst has been developed, tested and validated on population cohorts.A simple blood draw holds the promise of early detection of cancer in asymptomatic individuals and opens up the possibilities for successful treatments and improved survival .

Breast cancer is the most common malignancy in women worldwide. It has now surpassed lung cancer as the leading cause of global cancer incidence by 2020, with an estimated 2.3 million new cases, representing 11.7% of all cancers. In India, the incidence increased significantly between 1965 and 1985, almost by 50%. The estimated number of incident cases in India in 2016 was 118,000. According to data, breast cancer in India accounted for 13.5% (178361) of all cancer cases and 10.6% (90408) of all deaths in 2020.

Leave a Comment

Your email address will not be published.